🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)

RecruitingPhase 2Ages 18 Years - 70 YearsAllTakeda
NCT07633301 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Narcolepsy is a sleep disorder that disrupts a person's regular sleep-wake cycle. It causes extreme sleepiness during the day (called excessive daytime sleepiness \[EDS\]), where a person may fall asleep without warning. Narcolepsy Type 1 (NT1) is a form of the condition in which people also have sudden, unexpected muscle weakness while staying conscious (called cataplexy). The main aim of this study is to learn how safe TAK-360 is and how well adults with NT1 tolerate it. Adults who can participate in the study will have to stop taking their existing medicines for NT1 before study treatment starts. Participants may be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo during the treatment period. The placebo looks just like TAK-360 but does not have any medicine in it. After the treatment period, participants can be monitored for another 2 wee

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Key Inclusion Criteria: 1. The participant has a body mass index within the range 18 to 40 kilograms per meter square (kg/m\^2) (inclusive). 2. The participant has an International Classification of Sleep Disorders, Third Edition (ICSD-3) or ICSD-3 Text Revision diagnosis of NT1. Key Exclusion Criteria: 1. The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with excessive daytime sleepiness. 2. The participant: (a) has a history of myocardial infarction; (b) has a history of clinically significant thyroid disease, coronary artery disease, cardiac rhythm abnormality or heart failure. 3. The participant has a clinically significant history of head injury or head trauma. 4. The participant has a history of epilepsy, seizure, or convulsion (except for a single febrile seizure in childhood). 5. The participant has a history of cerebral ischemia, transient ischemic attack (\<5 years from screening), intracranial aneurysm, or arteriovenous malformation. 6. The participant has a history of cancer in the past 5 years (does not apply to participants with carcinoma in situ that has been resolved without further treatment or basal cell carcinoma; these participants may be included after approval by the medical monitor). 7. The participant has a positive test result for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus antibody, or human immunodeficiency virus (HIV) antibody/antigen at screening. 8. The participant plans to participate in any other interventional trial while participating in TAK-360-2004 or has previously participated in another part in TAK-360-2004. 9. The participant has a known hypersensitivity to any component of the formulation of TAK-360 or related compounds.
💊

What it tests

  • TAK-360
  • Placebo
📍

Where

18 sites
Takeda Site 12
Redwood City, United States
Takeda Site 14
Miami, United States
Takeda Site 13
Cincinnati, United States
Takeda Site 2
Macquarie Park, Australia
Takeda Site 4
Beijing, China
Takeda Site 3
Guangzhou, China
Takeda Site 5
Zhengzhou, China
Takeda Site 6
Herault, France

…and 10 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy